Mirra S S, Heyman A, McKeel D, Sumi S M, Crain B J, Brownlee L M, Vogel F S, Hughes J P, van Belle G, Berg L
VA Medical Center, Department of Pathology and Laboratory Medicine, Decatur, GA 30033.
Neurology. 1991 Apr;41(4):479-86. doi: 10.1212/wnl.41.4.479.
The Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a practical and standardized neuropathology protocol for the postmortem assessment of dementia and control subjects. The protocol provides neuropathologic definitions of such terms as "definite Alzheimer's disease" (AD), "probable AD," "possible AD," and "normal brain" to indicate levels of diagnostic certainty, reduce subjective interpretation, and assure common language. To pretest the protocol, neuropathologists from 15 participating centers entered information on autopsy brains from 142 demented patients clinically diagnosed as probable AD and on eight nondemented patients. Eighty-four percent of the dementia cases fulfilled CERAD neuropathologic criteria for definite AD. As increasingly large numbers of prospectively studied dementia and control subjects are autopsied, the CERAD neuropathology protocol will help to refine diagnostic criteria, assess overlapping pathology, and lead to a better understanding of early subclinical changes of AD and normal aging.
阿尔茨海默病注册协会（CERAD）神经病理学特别工作组已制定了一项实用且标准化的神经病理学方案，用于对痴呆症患者和对照受试者进行尸检评估。该方案提供了“确诊阿尔茨海默病（AD）”“很可能是AD”“可能是AD”以及“正常大脑”等术语的神经病理学定义，以表明诊断的确定性水平，减少主观解释，并确保使用共同的语言。为了对该方案进行预测试，来自15个参与中心的神经病理学家录入了142例临床诊断为很可能是AD的痴呆症患者以及8例非痴呆症患者的尸检大脑信息。84%的痴呆症病例符合CERAD确诊AD的神经病理学标准。随着越来越多经过前瞻性研究的痴呆症患者和对照受试者接受尸检，CERAD神经病理学方案将有助于完善诊断标准、评估重叠病理情况，并更好地理解AD和正常衰老的早期亚临床变化。
